Aids|OMICS International|Journal Of AIDS And Clinical Research

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Drug Resistance Of HIV

Highly active antiretroviral therapy (HAART) is the current standard of care for human immunodeficiency virus (HIV) infections. Although drug resistance may have been present before the introduction of antiretroviral (ARV) therapy due to random genetic variation, the introduction of ARV therapy exerts selective pressure over viral subpopulations to develop resistance. The use of HAART decreases the risk of resistance when compared with mono or dual therapy regimens. However, drug resistance remains an undesirable outcome of long-term therapy. Understanding and applying general principles in the proper use of ARV therapy will lessen drug resistance. While initially patients and clinicians have multiple regimens available to them, challenging situations arise when patients develop adverse reactions, intolerance, and decreased adherence and are choosing a new regimen to replace a failing one.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2021